Journal article
Beta blockade as adjunctive breast cancer therapy: A review
Critical reviews in oncology/hematology, Vol.138, pp.173-177
06/01/2019
DOI: 10.1016/j.critrevonc.2019.04.006
PMID: 31092374
Abstract
Pre-clinical data has shown that beta adrenergic stimulation can affect the development and progression of many types of cancer. The use of beta blockers as an anti-neoplastic therapy has been studied in retrospective trials and observational trials, but no definitive conclusions about efficacy have been made. Within the realm of breast cancer, significant advances in therapy have led to improved survival outcomes, yet there is room for improvement. Beta adrenergic blockade may prove an effective adjunct to standard breast cancer therapy, with little associated toxicity. This article provides a review of the published literature on beta blockade as an adjunctive cancer therapy, with a focus on breast cancer.
Details
- Title: Subtitle
- Beta blockade as adjunctive breast cancer therapy: A review
- Creators
- Sneha Phadke - Roy J. and Lucille A. Carver College of MedicineGerald Clamon - Roy J. and Lucille A. Carver College of Medicine
- Resource Type
- Journal article
- Publication Details
- Critical reviews in oncology/hematology, Vol.138, pp.173-177
- Publisher
- Elsevier
- DOI
- 10.1016/j.critrevonc.2019.04.006
- PMID
- 31092374
- ISSN
- 1040-8428
- eISSN
- 1879-0461
- Number of pages
- 5
- Grant note
- P30CA086862 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Language
- English
- Date published
- 06/01/2019
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359902002771
Metrics
18 Record Views